Hong Kong PR

KUALA LUMPUR, Sept 26, 2024 - (ACN Newswire via SeaPRwire.com) - The Clean Energy Transition Asia (CETA) Exhibition and Summit is set to take place  at the Kuala Lumpur Convention Centre (KLCC) from 9-11 October, 2024, uniting leaders from the clean energy sectors to accelerate Asia’s transition to a sustainable energy future. Co-located with the distinguished International Greentech & Eco Products Exhibition and Conference Malaysia (IGEM) 2024 and the MobilityX Asia, CETA will provide an integrated platform for both public and private stakeholders to collaborate on innovative solutions, driving sustainability and energy security across the region.This year’s event will closely align with Malaysia’s National Energy Transition Roadmap (NETR), positioning CETA as a key driver in the nation’s vision for energy transition. Launched last year by Prime Minister Datuk Seri Anwar Ibrahim, the NETR outlines a comprehensive strategy for achieving net-zero carbon emissions by 2050, and emphasises the importance of balancing economic growth with sustainability and energy security.  The Summit will serve as a platform to advance the country’s ambitious green energy agenda while setting a model for the region.McKinsey & Company and Rystad Energy join CETA as Knowledge Partner and Strategic Partner respectively, lending strength to the Summit with their key research and insights.Vishal Agarwal, Senior Partner at McKinsey & Company, stated, “Our assessment shows that in Asia alone, there is a potential for new value pools in green businesses worth $3 to $5 trillion in the next decade. This includes areas such as renewables, green data centres, electrification and transportation, and green materials.”Mel Lanvers-Shah, CEO of The Co_Lab Pte Ltd, the event's owner and organizer, emphasised, “CETA’s alignment with Malaysia’s National Energy Transition Roadmap demonstrates the crucial role that industry collaboration plays in achieving our collective sustainability goals. Together, we can build on the NETR's vision and extend its impact across Asia through the CETA platform.”Key themes addressed at the Summit include Policy & Energy Leadership, RE Ramp Up, The Hydrogen Economy, Financing Zero, Carbon, Transition Bridge and CASE Mobility Futures (a Connected Autonomous Shared Electric Mobility future for ASEAN).The Summit sessions will include top-level Ministerial Keynotes, Global Leadership Keynote Addresses, Global Leadership Panels and invitational Minister CEO Leadership Roundtables.Vijay Krishnan, Partner and Head of Asia Pacific at Rystad Energy, who is also speaking at the CETA Summit, noted,“Rystad Energy anticipates a continued rise in emissions, but expect them to decline afterward. Unfortunately, some key developed nations have shifted focus away from decarbonisation, emissions management and ESG principles. This shift in rhetoric is beginning to impact ASEAN, which is a significant concern we are committed to addressing at CETA.”“CETA's emphasis on adopting a whole-of-energy approach mirrors Malaysia’s NETR goals, particularly in its focus on balancing the development of clean energy technologies with the responsible use of hydrocarbons,” added Mel Lanvers-Shah.“Through innovative discussions and partnerships, the summit aims to accelerate the deployment of renewable energy projects, such as solar and wind, while fostering technologies like carbon capture and storage (CCS) to ensure a smooth transition in line with Malaysia's 2050 net-zero ambitions.”The IGEM, CETA and MobilityX Exhibition will feature over 500 exhibitors and sponsors, and is expecting an audience size of nearly 50,000 attendees, including energy professionals from across the region, with a view to exploring and procuring critical solutions that will help them grow their businesses.Organised by The Co_Lab Pte Ltd, CETA is held under the patronage of the Ministry of Natural Resources and Environmental Sustainability (NRES), with the Malaysian Green Technology and Climate Change Corporation (MGTC) as its strategic partner and PETRONAS as its Industry Patron.To register and for more information, please visit www.ceta.asiaAbout CETAThe Clean Energy Transition Asia (CETA) Exhibition and Summit is the premier event in Asia focused on driving the region’s energy transition by uniting the clean energy and hydrocarbon sectors. CETA aims to accelerate sustainability efforts across the region by aligning with national strategies, such as Malaysia’s NETR, to ensure a just, secure, and affordable future for all.Co-located with the International Greentech & Eco Products Exhibition & Conference Malaysia (IGEM) 2024 and MobilityX, CETA is under the esteemed patronage of the Ministry of Natural Resources and Environmental Sustainability (NRES) Malaysia.Adopting an integrated, whole-of-energy approach, CETA will bring together the clean energy and hydrocarbons sectors through an exhibition and summit focused on four key pillars critical to the region's energy transition: Renewable Energy Ramp-Up, Hydrogen, Carbon, and Transition Fuels. About IGEMIGEM has established itself as Southeast Asia’s largest trade event for green technologies and eco solutions. Over the years, IGEM has successfully generated close to RM41 billion in business leads since its inception in 2010. To date, IGEM has attracted over 530,000 visitors, including delegates, dignitaries, and companies from more than 112 countries. For media enquiries, please contact marcomms@ceta.asia. Copyright 2024 ACN Newswire via SeaPRwire.com.

KUALA LUMPUR, Sept 26, 2024 - (ACN Newswire via SeaPRwire.com) - MobilityX 2024 is set to take center stage as one of the most anticipated exhibitions and summits in the electric vehicle (EV) industry, bringing together global leaders, innovators, and policymakers to explore the future of clean mobility at the Kuala Lumpur Convention Centre (KLCC) from 9-11 October, 2024. Co-located with the International Greentech & Eco Products Exhibition & Conference Malaysia (IGEM) and the Clean Energy Technology Asia (CETA) summit, MobilityX will highlight the latest advancements in the clean mobility market, facilitate cutting-edge partnerships, and ignite discussions that will shape the mobility landscape in Southeast Asia.As Southeast Asia positions itself as a rising global hub for the electric vehicle industry, MobilityX 2024 will serve as a premier platform for stakeholders to exchange insights on EV trends, technology advancements, and policy frameworks that are driving the sector forward. From OEM automakers to energy providers, government bodies to tech innovators, the event will feature groundbreaking innovations that address the growing demand for clean, sustainable mobility solutions.MobilityX  2024 will play a critical role in supporting Malaysia’s aspirations as outlined in the National Energy Transition Roadmap (NETR), which identifies green mobility as a key pillar of the country’s sustainable development strategy. The event will showcase how the growing EV ecosystem can help operationalise a low-carbon transport system, aligning with Malaysia’s goal of achieving net-zero carbon emissions by 2050.“Electric vehicles are steering nations towards a cleaner future, and Malaysia has the right foundations in place to build a low-carbon transport infrastructure,” said Mel Lanvers-Shah, CEO of The Co_Lab Pte Ltd, the event’s owner and organiser.  “With the support of initiatives like MobilityX  and collaboration among industry leaders, we are well on track to establish Southeast Asia as a leader in future mobility.”As a dynamic platform for innovation, MobilityX  2024 will feature interactive exhibits, product launches, and expert panels at the co-located CETA Summit discussing the latest technologies shaping the future of mobility. Topics will include the integration of electric vehicles into smart cities, advancements in EV charging infrastructure, and the role of autonomous and connected vehicles in reducing emissions and transforming urban transport.In addition to showcasing technological advancements, MobilityX 2024 will foster cross-industry collaborations and partnerships essential to accelerating the global EV transition. It will provide opportunities for OEMs, Mobility Innovators, After Market Suppliers and Technology Providers to network and engage in strategic dialogues that address both the challenges and opportunities facing the clean mobility sector.With Southeast Asia on the cusp of a mobility revolution, Malaysia stands at the forefront of this transformation. MobilityX  2024 is set to cement the nation’s role as a leading player in the global EV market, propelling the region towards a sustainable, low-carbon future.The IGEM, CETA, and MobilityX  Exhibition and Summit is set to welcome nearly 50,000 attendees, with over 500 exhibitors and sponsors showcasing cutting-edge solutions. Energy professionals from across the region will gather to explore innovations and secure the resources needed to drive business growth and sustainability in the industry.Organised by The Co_Lab Pte Ltd, MobilityX  is held under the patronage of the Ministry of Natural Resources and Environmental Sustainability (NRES), with the Malaysian Green Technology and Climate Change Corporation (MGTC) as its strategic partner.To register and for more information, please visit www.mobilityx.asia. About MobilityXMobilityX  is an annual exhibition and summit focused on future and clean mobility and electric vehicle innovations, driving the mobility transition across Asia.  Co-located with IGEM and CETA, MobilityX  brings together OEMs, Mobility Innovators, After Market Suppliers and Technology Providers from around the region to explore the latest trends and technologies shaping the future of mobility.For media enquiries, please contact marcomms@mobilityx.asia. Copyright 2024 ACN Newswire via SeaPRwire.com.

TEL AVIV, IL, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - A2Z Cust2Mate Solutions Corp. ("A2Z") (NASDAQ:AZ)(FRA - WKN:A3CSQ), a global leader in innovative technology solutions, today announced it has signed global framework agreements with Nayax Capital, ("Nayax Capital"), whereby Nayax Capital will enable financing for the sale or lease of Cust2Mate smart carts enabled with Nayax’s complete solution.This announcement is further to the company’s press release on September 10, 2024 announcing the formation of a joint venture with Nayax Ltd. to mutually promote the sales of A2Z Cust2Mate’s smart cart solution integrated with Nayax’s payment solution for on-cart payments. The joint venture announcement can be read here.Under the terms of the framework agreements, Nayax Capital will enable retailers to pay or lease the Cust2Mate smart carts that are sold as part of a comprehensive solution, which includes Nayax’s payment, management and loyalty solution, in monthly installments. The framework agreements cover the A2Z Cust2Mate’s smart carts, charging solutions, and IT infrastructure upgrades, as needed, for customers around the world including Europe, North America and Latin America. Any financing extended is subject to individual terms and conditions and approval by Nayax Capital and is non-recourse to A2Z.Gadi Graus, CEO of A2Z, stated, “We have teamed up with Nayax Capital to help merchants grow by making it easier for retailers around the globe to adopt our smart cart solution. With a readily available financing option, approved retailers can move quickly to implement our smart carts and begin realizing tangible benefits to their operations and improve the shopping experience for their customers.”About A2Z Cust2Mate Solutions Corp.A2Z Cust2Mate Solutions Corp. brings innovation, ease, excitement and value to retailers and shoppers. The Company is transforming brick-and-mortar retail with innovative smart shopping cart solutions that digitize the in-store shopping experience. The proven-in-use, friendly, sensor rich, AI driven carts enhance customer satisfaction and loyalty, minimize shrinkage, optimize retailers' operations and enable new business models. The smart carts streamline in-store shopping by enabling in-cart scanning and payment, allowing users to bypass checkout lines while alleviating labor shortages. Retailers can optimize merchandising, store layouts and promotions from data-driven insights, while shoppers get real-time information and personalized offers, turning a necessary chore into a fun and rewarding experience.For more information on A2Z Cust2Mate Solutions Corp. (NASDAQ:AZ)($AZ)(FRA - WKN:A3CSQ) and its subsidiary, Cust2mate Ltd., please visit, please visit www.cust2mate.com.Cautionary Statement Regarding Forward-looking StatementsMatters discussed in this press release may contain forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including whether the referenced patent will be granted. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the Company's filings on EDGAR and with the SEC. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. Forward-looking statements contained in this announcement are made as of this date, and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein.About NayaxNayax is a global commerce enablement, payments and loyalty platform designed to help merchants scale their business. Nayax offers a complete solution including localized cashless payment acceptance, management suite, and loyalty tools, enabling merchants to conduct commerce anywhere, at any time. As a global leader in serving unattended retail, Nayax has transformed into a comprehensive solution focused on our customers’ growth across multiple channels. As of June 30, 2024, Nayax has 11 global offices, approximately 1,100 employees, connections to more than 80 merchant acquirers and payment method integrations and is globally recognized as a payment facilitator. Nayax’s mission is to improve its customers’ revenue potential and operational efficiency. For more information, please visit www.nayax.com.Issued By: Swan Consultancy Sdn. Bhd. on behalf of A2Z Cust2mate Solutions Corp. and Nayax Ltd.For more information, please contact:Mandy TanEmail: m.tan@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

ANKARA, Turkey, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the positive results of its Phase 2 clinical trial evaluating the safety and efficacy of its investigational drug, GN-037 topical cream, in treating mild to moderate plaque psoriasis. The findings were presented at Amsterdam's European Academy of Dermatology and Venereology (EADV) 2024 Congress.GEN PharmaceuticalsGEN Pharmaceuticals Manufacturing FacilityThis multicenter, randomized, double-blind, placebo-controlled Phase 2 study involved 190 patients across 19 clinical centers in Türkiye. Patients were treated with GN-037, clobetasol 17-propionate, or placebo twice daily for four weeks, followed by an additional four-week observation period. The study demonstrated GN-037's statistically significant superiority in reducing psoriasis symptoms compared to placebo, positioning it as a promising new treatment option for psoriasis patients worldwide.Key Findings:The GN-037 Phase 2 trial met the primary endpoint: treatment success,defined as the percentage of patients with at least a 2-grade improvement in Investigator's Global Assessment (IGA) score and achieving an IGA score of 0 or 1.37.9% of patients treated with GN-037 achieved treatment success at week four compared to 9.1% in the placebo group (P=0.006).GN-037 demonstrated significant improvements in reducing erythema (57.6%, P=0.008), plaque elevation (72.7%, P=0.001), and scaling (80.3%, P=0.006) compared to placebo.31.8% of patients in the GN-037 group achieved at least a 75% reduction in PASI, compared to 6.1% in the placebo group (P=0.009).No new safety concerns emerged with similar treatment-emergent adverse events across all arms.Abidin Gülmüs, Chairman of GEN, stated: "We are thrilled to announce the positive results of our Phase 2 clinical trial. We believe GN-037 offers new hope for the global psoriasis community."Nadir Ulu, MD, PhD, Vice President of R&D, added: "Our Phase 2 trial results highlighted GN-037's potential to improve patient outcomes significantly, and it may provide a novel, well-tolerated treatment option for patients with mild to moderate plaque psoriasis."About GEN:Founded in 1998, GEN is Türkiye's leading speciality pharmaceutical company. It is focused on developing innovative therapies across multiple therapeutic areas, with significant R&D investments and a commitment to advancing global healthcare. GEN actively works in both in-licensing and out-licensing business models. GEN partners with leading global pharmaceutical companies to bring innovative therapies and rare solutions to communities in its countries. It also develops and produces highly demanded and competitive therapeutic products in its GMP-certified manufacturing facility to bring therapy solutions required in international markets.For more information, visit www.genilac.com.tr.For inquiries:Bulutay GÜNES, Head of Corporate Brand, b.gunes@genilac.comAli KETENCIOGLU, Investor Relations Manager, a.ketencioglu@genilac.comContact InformationBulutay GunesHead of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comSOURCE: GEN Pharmaceuticals Copyright 2024 ACN Newswire via SeaPRwire.com.

SELANGOR, Malaysia, Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - OSK Property is excited to announce its partnership with PeopleUp, a leading multi-enrichment and play group founded in 2018 in Singapore. Together, they will introduce a brand-new regional play brand to Atria Shopping Gallery in Petaling Jaya, marking PeopleUp’s FIRST expansion beyond Singapore. This groundbreaking entertainment hub will cater to families and kids, creating a one-stop destination for fun, learning, and holistic family experiences.1. Ong Ju Xing, Deputy Group Managing Director, OSK Holdings Berhad2. Samantha Lew Pey Shin, General Manager, Group Retail Leasing, OSK Property Investment3. Chris Tan Wei Quan, Chief Executive Officer, PeopleUp4. Loh Wai Keong, Managing Director & Chief Executive Officer, Greenwillow Capital Management[L-R]The signing ceremony took place at Atria Shopping Gallery and the agreement was executed between OSK Property Investment, Group Retail Leasing General Manager Samantha Lew Pey Shin and PeopleUp Singapore Chief Executive Officer Chris Tan Wei Quan. The event was witnessed by OSK Group Deputy Group Managing Director Ong Ju Xing and Greenwillow Capital Management Managing Director Loh Wai Keong.PeopleUp has successfully set its footprint in Malaysia, thanks to its regional strategic partners, Arkwood Trustee (M) Berhad and Greenwillow Capital Management. These two companies are backed by key figures, Sunny Yeo, Chief Executive Officer and Managing Director of Arkwood Trustee, and Loh Wai Keong, Managing Director of Greenwillow.With over 16 thriving subsidiary brands in Singapore, PeopleUp has earned its reputation for delivering innovative, engaging, and memorable experiences for families. Its flagship brands, such as Bouncy Paradise - Asia’s largest inflatable playground - and Dinoland - Singapore’s first immersive and largest indoor dinosaur park with live forest, along with VroomTown, the first mega indoor drive-play city for kids, have welcomed over half a million visitors annually.Set to open in the first half of 2025, the new expansion will build upon this success, showcasing exciting, family-oriented concepts from Singapore and introducing new experiences tailored to the Malaysian market.OSK Property Investment Group Retail Leasing General Manager Samantha Lew said "At OSK Property, we are committed to curating spaces that bring value and excitement to the community. Partnering with PeopleUp is an exciting step forward in transforming Atria Shopping Gallery into a choice destination for families. This new play concept will enhance the mall’s position as a leading family-friendly venue, attracting visitors from across the region."Chris Tan Wei Quan, Chief Executive Officer of PeopleUp Singapore, expressed his enthusiasm for the expansion: "We are thrilled to bring our unique, holistic approach of family entertainment to Malaysia. The collaboration with OSK Property allows us to share our vision and passion for innovative play and enrichment with a wider audience. We are confident that this flagship will resonate with families and set a new benchmark for family entertainment in the region."Anchoring over 60,000 square feet within Atria Shopping Gallery, PeopleUp will see the creation of an exciting new flagship family destination that encapsulates a wide array of fun, entertainment, and learning experiences. The flagship will bring together six key areas designed to cater to every type of play:Kids & Toddler Play: A safe and engaging environment for younger children to explore.Sports Play: Promoting active play and physical fitness through dynamic sports activities.E-gaming and Immersive Play: Combining cutting-edge technology with play for a thrilling digital experience.Sky Play: Adventure high above the ground with elevated play areas.Water Park: A fun-filled aquatic adventure for families.Special Experiences: Unique, curated experiences that will surprise and delight visitors.In addition to these fresh and exciting concepts, PeopleUp will also introduce its popular Singapore-based attractions to Atria Shopping Gallery, tailoring them to fit the tastes and preferences of the local market.These zones will offer an all-encompassing mix of physical, mental, and sensory experiences for children of all ages, the new flagship destination will set a new standard for family entertainment in Malaysia.OSK Property’s strategic partnership with PeopleUp is a testament to the growing demand for family-centric leisure destinations in Malaysia. By combining PeopleUp's award-winning concepts with OSK Property’s vision, Atria Shopping Gallery hopes to become the top destination for families seeking fun and enriching experiences.For more information, please visit Atria Shopping Gallery’s website at www.atria.com.my and PeopleUp Singapore's website at www.peopleup.com.sg About Atria Shopping GalleryAtria Shopping Gallery is a transformation of yesterday’s beloved iconic mall in Petaling Jaya to cater to today’s more sophisticated and discerning tastes. The Shopping Gallery’s beautiful interior is inspired by the natural beauty and exquisite forms found in our tropical rainforest, creating a sense of natural opulence and an ambience that is warm and welcoming. Atria strives to offer shoppers a total experience and has in place tenants, activities and an environment that we hope will leave our shoppers feeling relaxed, inspired and enriched.About the Developer – OSK PropertyOSK Property is the property arm of the OSK Group which is a public listed company in Malaysia with an asset size over RM 10 billion. OSK Property is one of Malaysia’s leading property groups that has completed and delivered more than 50,000 properties across Malaysia and Australia. With a diverse portfolio that spans residential, commercial, hospitality, industrial and mixed-use developments, OSK Property is committed to delivering innovative and engaging spaces that enhances the way of life of communities.With each project, OSK Property continues to seek and prioritize its sustainability strategy incorporating the integration of sustainable design features, minimizing our environmental footprint by incorporating advanced technologies and infusing the natural elements such as shadow play and wind flow, and utilizing environmentally friendly materials to ensure the overall health and well-being of occupants. For further information, visit OSK Property’s website at www.oskproperty.com.myIssued By: Swan Consultancy Sdn. Bhd. on behalf of OSK PropertyFor more information, please contact:Jazzmin WanTel: +60 17-289 4110Email: j.wan@swanconsultancy.bizAsyraf HakimiTel: +60 11-23774173Email: a.hakimi@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.

BOYERTOWN, Pa., Sept 25, 2024 - (ACN Newswire via SeaPRwire.com) - Global Advanced Metals (GAM), a leading global producer of metallurgical products, is pleased to announce a new partnership with the U.S. Department of Defense (DOD) to re-establish defense-critical niobium oxide production. The project, supported by a $26.4 million award from the Manufacturing Capability Expansion and Investment Prioritization directorate, leverages GAM's existing tantalum production in Boyertown, Pennsylvania.GAM LogoThe DOD's capital contribution will accelerate the development of the United States' first niobium oxide production in over 30 years. Niobium oxide is a precursor to high-purity superalloys in advanced aircraft, rocket systems, and various other defense platforms. GAM's public-private partnership forms a key component of the DOD's ongoing efforts to solidify the U.S. aerospace and defense industrial base."GAM is proud to contribute to strengthening U.S. and allied capability by mitigating supply vulnerabilities previously exploitable by our adversaries," said GAM's CEO, Andrew O'Donovan. "Every opportunity to decrease adversarial influence over defense supply chains should be taken, and we are delighted that the DOD chose to support GAM in this endeavor.""Pennsylvania has built and powered our Nation for generations, so it's no surprise that workers in Berks County will soon produce critical minerals to make the aircraft, rocket systems, and other equipment our military needs to ensure our national security," said U.S. Senator Bob Casey (D-PA). "I advocated for our Commonwealth to tackle this critical mineral risk so that we can continue the proud tradition of supporting our warfighters and the Department of Defense as a whole.""As a former chemistry teacher and Air Force officer, I've been championing efforts on critical mineral supply chains and the importance of bringing related manufacturing back to the U.S. since I first arrived in Congress," said U.S. Congresswoman Chrissy Houlahan (D-PA). "So when I visited Global Advanced Metals (GAM) in Berks County last year, I was in awe of their state-of-the-art operations - I knew GAM and companies like them have the blueprint we need to reduce reliance on countries like China for critical minerals. I'm so thrilled to hear GAM is receiving a $26.4 million award for niobium processing and manufacturing of defense-critical materials! With this federal investment, more jobs in our community will be created and our national security will be strengthened."About GAMA leading conflict-free tantalum producer, GAM has exclusive rights to the world's largest industrial resources of tantalum ore located in Western Australia.GAM produces conflict-free tantalum powders and metallurgical products at its Pennsylvania, USA and Aizu, Japan plants for a range of industries including electronics, aerospace, automotive, medical and chemical processing.GAM's smelting facilities in Japan and the USA were first declared "Conflict-Free" in 2010 under the former EICC/GeSI Conflict-Free Sourcing Initiative (CFSI) audit program and continue to maintain their conformance to the current Responsible Minerals Assurance Process (RMAP) standard.Contact InformationKurt HabeckerSr. Marketing Managerkhabecker@globaladvancedmetals.com1 610-369-8220SOURCE: Global Advanced Metals Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年9月24日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（"本公司"，連同其附屬公司統稱為"本集團"或"康哲藥業"）欣然宣佈，磷酸蘆可替尼乳膏（"蘆可替尼乳膏"或"產品"）（白癜風適應症）新藥上市許可申請（NDA）已於2024年9月24日獲得中國國家藥品監督管理局（NMPA）受理。這是產品繼白癜風適應症獲海南省藥監局批准臨床急需進口，及在澳門獲批上市等系列里程碑事件之後的又一重磅進展，也是邁出惠及中國逾千萬白癜風患者的關鍵一步。蘆可替尼乳膏在中國真實世界研究中取得了積極結果。治療組主要療效指標第24周達到F-VASI 75的患者比例為49.5%，顯著高於目標值14.1%（P<0.0001），研究達到了主要終點，證明產品能夠有效治療非節段型白癜風患者，縮小皮損面積，恢復膚色。所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢，且治療時間越長，患者的白癜風治療效果持續改善。不良反應的嚴重程度大部分均為1級或2級，未發生導致停藥或退出的不良事件（AE），未發生研究藥物相關的嚴重不良事件（SAE）。在推進產品新藥上市申請進程的同時，本集團針對蘆可替尼乳膏的境外生產藥品轉移至境內生產（地產化技術轉移）工作正在委託合同研發生產外包組織（CDMO）有序推進中，目前已完成小試和中試研究，正在進行放大生產。本集團爭取早日完成地產化研究，在中國大陸註冊並獲得上市批准，讓中國白癜風患者用上創新產品。白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。據估算，中國白癜風患者約1,400萬[1]。白癜風患者中約85%為非節段型白癜風。外用皮質類固醇（TCS）及鈣調神經磷酸酶抑制劑（CI）均為非節段型白癜風的標籤外用藥，然而，這些現有外用藥物療法有長期用藥的不良反應或療效有限的臨床痛點[2、3]。若中國獲批上市，產品有望成為中國大陸獲批的首個用於白癜風複色的處方藥，將為中國廣大白癜風患者帶來治療新曙光。康哲藥業始終堅持以提供有競爭力的產品和服務，滿足尚未滿足的醫療需求為使命，在創新發展戰略的指導下，不斷加強自主研發與外部合作，豐富產品管線。未來，康哲藥業將繼續在全球範圍內識別具有差異化優勢的醫藥產品，並高效推動產品臨床開發和商業化發展，為患者帶來更多新藥、好藥。關於蘆可替尼乳膏蘆可替尼乳膏（Opzelura），為Incyte的JAK1/JAK2選擇性抑制劑蘆可替尼的創新乳膏製劑，已獲得美國食品和藥物管理局（FDA）批准用於12歲及以上非節段型白癜風患者的局部治療。截至目前，蘆可替尼乳膏是首個也是唯一一種在美國獲批使用的白癜風複色產品[4]。此外，蘆可替尼乳膏（Opzelura）在美國獲批用於傳統外用處方療法不可取或不能充分控制病情之12歲及以上非免疫功能低下的輕中度AD患者的局部短期和非持續性慢性治療[5]。蘆可替尼乳膏（Opzelura）也於歐洲獲批用於12歲及以上青少年及成人患者伴面部受累的非節段型白癜風的治療[6]。雖然NMPA未批准產品在中國大陸的任何適應症藥物的上市，但是產品此前於2023年8月12日獲得海南省藥監局批准臨床急需進口，並於8月18日正式落地海南博鼇樂城國際醫療旅遊先行區，用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的局部治療。受益于國家賦予海南自由貿易港、海南博鼇樂城國際醫療旅遊先行區"先行先試"特許政策，中國白癜風患者可在博鼇超級醫院先行申請使用產品並接受專家團隊的治療。此外，蘆可替尼乳膏亦於2024年4月11日獲得澳門政府藥物監督管理局（ISAF）批准新藥上市申請，用於治療12歲及以上青少年和成人患者伴面部受累的非節段型白癜風。本集團於2022年12月2日，通過本公司附屬公司-康哲美麗與Incyte就用於治療自身免疫性炎症皮膚病的蘆可替尼乳膏製劑訂立合作和許可合約（"許可合約"）。根據該等許可協議，本集團通過康哲美麗獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國（印尼、菲律賓、越南、泰國、緬甸、馬來西亞、柬埔寨、老撾、新加坡、東帝汶以及汶萊）（"區域"）開發、註冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。許可協議期限開始於許可協議生效日，自產品在區域內首次商業化銷售之日起擁有十年的授權期限（"授權期限"）。授權期限屆滿後，根據許可協議約定的特定條件，許可協議期限可延長十年（"初始延展授權期限"）。初始延展授權期限屆滿後，根據許可協議約定的特定條件，雙方可另行協商許可協議的延長期限。Incyte擁有產品的全球開發和商業化權利，在美國和歐洲以Opzelura的名稱銷售。Opzelura及其logo是Incyte的注冊商標。關於康哲藥業康哲藥業是一家連結醫藥創新與商業化，把控產品全生命週期管理的開放式平臺型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的管道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化業務競爭力，並將皮膚醫美、眼科業務獨立運營，培育專科小領域的大龍頭，提升專科規模效率。同時業務版圖拓展至東南亞市場，著力成為全球藥企進軍東南亞市場的"橋頭堡"，助力康哲藥業高品質持續健康發展。參考文獻：1、Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-72、《白癜風診療共識（2021版）》3、Kubelis-Lopez DE, Zapata-Salazar NA, Said-Fernandez SL, Sanchez-Dominguez CN, Salinas-Santander MA, Martinez-Rodriguez HG, Vazquez-Martinez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.4、FDA批准資訊可在FDA官網查詢，網址如下：https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older5、FDA批准資訊可在incyte官網查詢，網址如下：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream6、EMA批准資訊可在EMA官網查詢，網址如下：https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療資訊，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及資料編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及本集團的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。本集團並不採納本新聞包含的協力廠商所做的任何前瞻性聲明及預測，本集團對該等協力廠商聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.

QUAKERTOWN, PA, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - At the start of 2024, DEXIS introduced its digital ecosystem, a suite of tools and software designed to connect and streamline the implant workflow from diagnosis to delivery.Today, DEXIS announced upgrades across the ecosystem to aid clinicians in important workflow elements from visualizing progressive dental issues to designing chairside surgical guides."Our technology makes it easy to organize information and execute treatments, which is at the core of what clinicians expect from us," said DEXIS President, Robert Befidi. "We are connecting and standardizing the implant workflow while also constantly evaluating our efforts to ensure we provide deeper patient insights and flexible, intuitive solutions that reduce complexity. These three launches are a good example of our focus on continuous innovation across the ecosystem to deliver diagnostic confidence, productivity, and smart simplicity."A brand-new X-ray platform is now available, designed specifically for general practitioners looking to expand their diagnostic capabilities with 3D imaging. Developed and produced in Tuusula, Finland, the ORTHOPANTOMOGRAPH™ OP 3D™ EX captures consistently accurate images through a straightforward, easy-to-learn workflow. The unit has a wide range of field of view sizes to support multiple clinical indications, including implant placement, endodontics, periodontics, and analysis for airway and TMJ. Early adopters of the OP 3D EX have reported positive feedback:"When choosing a CBCT, the key factors for me were a large sensor, predictable acquisition, stellar image quality and intuitive software that wouldn't interrupt my workflow," says Dr. Tyler Tolbert of Smile Now Dental Group. "Once the OP 3D EX got here and we started taking some scans, I thought to myself, ‘We really made the right choice here!'"In addition to new hardware, a brand-new software release will provide advanced tools to plan and execute same-day, prosthetically driven implants.Serving as the unifying software and central hub of the ecosystem, DTX Studio™ Clinic stores and manages all patient data as well as helps clinicians execute each step of the implant process from diagnostics to delivery.The software's new functionality allows practitioners to plan an implant treatment and generate a surgical guide chairside - all in less than three minutes. Clinicians can virtually extract teeth, adjust photorealistic abutments and crowns, and create an automated surgical guide that can be sent to a lab or produced in-house for same-day delivery."We were able to implement the OP 3D EX quickly and start taking scans largely due to the included DTX Studio Clinic software," said Dr. Nicholas Varney of Varney Dental. "Once we got going, we found that so much of the work involved in prepping a 3D scan for confident diagnosis was done by the software automatically. DTX Studio Clinic has improved how we work in all aspects - communicating with patients, implant planning and even treatment team collaboration."In addition to 3D imaging enhancements, an intraoral scanning software update offers scan quality and usability improvements as well as clear visualizations of progressive dental issues over time, through a new tool called Oral Compare. Additionally, the software's new integration with SmileFy allows for the ability to simulate treatment outcomes chairside, giving patients further confidence in proposed treatment plans.To learn more about DEXIS and the latest implant workflow upgrades, visit https://www.dexis.com.About DEXISDEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging, intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, please visit dexis.com.About Envista Holdings CorporationEnvista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide array of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.Contact InformationMaria PenalozaMedia & Content Strategy Managermaria.penaloza@issuerdirect.comSOURCE: DEXIS Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). This is another substantial milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo, and it is also a key step in benefiting over ten million of patients with vitiligo in China.Ruxolitinib cream achieved positive results in Chinese Real-World Study. The primary efficacy endpoint was the proportion of patients in the treatment group who achieved F-VASI 75 response at week 24, which was 49.5%, significantly higher than the target value of 14.1% (p<0.0001). The study met its primary endpoint, demonstrating that ruxolitinib cream is effective in treating patients with nonsegmental vitiligo, reducing the area of the lesions, and repigmenting the skin. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.While advancing the process of NDA for the Product, the Group is conducting the transfer of ruxolitinib cream from overseas production to domestic production (localization technology transfer), which is being orderly promoted by the Contract Development Manufacturing Outsourcing Organization (CDMO), and the lab-scale and pilot trial studies have been completed and under scale-up production. The Group strives to complete the localization study as soon as possible, register in Mainland China and obtain marketing approval, so as to enable the Chinese patients with vitiligo to use the innovative product.Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[1]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[2,3]. If the Product being successfully approved for marketing in China, it will be the first prescription drug approved for repigmentaton in vitiligo in Mainland China, bringing novel treatment hopes for Chinese vitiligo patients.CMS has always adhered to its mission of providing competitive products and services to meet unmet medical needs. Guided by innovation strategy, the Group continuously strengthens its independent R&D as well as external collaboration, enriching its product pipelines. Looking ahead, CMS will continue to identify products with differentiated advantages globally and efficiently promote their clinical development and commercialization, bringing more novel and effective drugs to patients.About ruxolitinib creamRuxolitinib cream, (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, and is the first and only treatment for repigmentation approved for use in the United States[4]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[5]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[6].The Product is not approved by the NMPA for any indication in Mainland China. However, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”) on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. In addition, ruxolitinib cream was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024 for the topical treatment of non-segmental vitiligo with facial involvement in adult and adolescents form 12 years of age.On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the  License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference：1 Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-72 Consensus on the diagnosis and treatment of vitiligo (2021 version)3 Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.4 Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older 5 Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 6 Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Sept 24, 2024 - (ACN Newswire via SeaPRwire.com) – Hong Kong traders remain optimistic about their prospects with a sustained period of moderate growth believed to be underway. This was the key finding of the Hong Kong Trade Development Council (HKTDC) Export Confidence Index for the third quarter of 2024 as released today.The Index – a quarterly review of the views and expectations of Hong Kong-based traders across a broad cross-section of industry sectors – showed that, despite a slight decline compared to the second quarter, underlying sentiment remains broadly positive. In another welcome outcome, the majority of the sub-indices remained in expansionary territory, a clear indication of widespread anticipation of continued growth.Putting the overall findings into context, Irina Fan, Director of HKTDC Research, said: “Hong Kong exporters remain resilient, despite the uncertainty stemming from lingering trade tensions. Indeed, the majority of respondents reported no – or only minimal – impact from the recent round of trade restrictions and higher tariffs.”Strong sales and new ordersLooking at the findings in greater detail, the overall Current Performance Index rose by 1 point to 52.6, a development seen as reflecting strong sales and new orders, rising unit prices and expanding procurement activities. This was underlined by concurrent rises in the relevant Sub-Indices – the Trade Value Sub-Index (56.2, +2.5) and Procurement Sub-Index (57.3, +3.3). Although the Sales & New Orders Sub-Index recorded a moderate 1.8-point drop, it stayed resolutely in expansionary territory at 55.7.The Expectation Index also remained in expansionary territory at 51.4 even after a 2.9-point dip. This decrease was driven mainly by the 8.5-point decline in the Trade Value Expectation Sub-Index (down to 51.7), with traders expecting unit prices to increase only moderately.The same traders, however, remained optimistic about the outlook for sales and new orders (with a Sales & New Orders Expectation Sub-Index reading of 54.6); and look set to continue to expand their procurement activities (Procurement Expectation Sub-Index: 55.4).Overall, the findings suggest that the immediate future will be characterised by moderate, sustained export growth.Cost pressures lessen, but remain major concernIt was also apparent that costs remained the major drag on exporter confidence in the third quarter. While both the Current and Expectation Cost Sub-Index showed some improvement, scores remained at about the 35 level, an indication that exporters are still facing strong cost pressures.In terms of Current Performance, exporters have seen increased Sales and New Orders across all their key markets. With regard to outlook (Expectation), exporters were most upbeat about the ASEAN bloc (59.7) and mainland China (58.4).By industry, the third quarter saw an improvement in Current Performance across all sectors. In terms of prospects for the near-term, Clothing exporters are the most optimistic at 61.2, followed by Toys (58.7) and Jewellery (56.4).Looking to the immediate future, Nicholas Fu, Senior Economist with HKTDC Research, said: “Exporters from five out of the six key sectors expect the current positive business momentum to continue. Overall, Clothing exporters were the most upbeat, followed by those in the Toys and Jewellery sectors. While it is noteworthy that cost pressures are expected to stay high across all sectors, there is some possibility of a slight improvement further down the line.”In addition to addressing the standard index criteria, the latest survey also focused on several specific thematic questions with regard to the primary challenges facing exporters and the favoured forward strategies of participants. Responses here showed that:- High and rising costs (transport, labour, production and capital) were seen as the most significant challenges.- In order to mitigate any related risks, Hong Kong exporters intend to adopt more cautionary business strategies.- Regarding the impact of recent trade restrictions and higher tariffs on certain China-origin exports, 60% of respondents reported no impact on their business to date, while 39% expect only a moderate downside.- On the sustainability front, however, fewer than 20% of respondents were familiar with the EU's newly enacted Ecodesign for Sustainable Products Regulations (ESPR), which is expected to have a broad impact across many industry sectors.Notes for EditorsThe HKTDC Export Confidence Index was introduced in the first quarter of 2024. It is a composite of five sub-indices – Sales and New Orders, Trade Value, Cost, Procurement and Inventory – and seeks to provide a comprehensive overview of Hong Kong exporter sentiment.There are two primary / overall indices, one of which gauges the Current Performance in the present quarter, while the other considers the Expectation for the upcoming quarter via a weighted average of the following five sub-indices:- Sales and New Orders: This is an indication of overall export performance as well as the level of new export orders received by respondents. This index is compiled based on respondents' feedback regarding the prospects of each of their major export markets.- Trade Value: This focuses on tracking the movement of unit export prices.- Cost: This tracks cost pressures as they relate to day-to-day operations, including raw material prices / labour and other operational costs/ financing requirements. Compared with the other indices, it is an inverted index, with an index reading above 50 indicating a downward trend for costs, while a reading below 50 indicates an upward trend for costs.- Procurement: This is a measure of the input-buying activity of Hong Kong traders.- Inventory: This tracks the overall inventory levels held by respondents for present use and the upcoming quarter. An index reading above 50 indicates a lower-than-normal inventory level, while a reading below 50 indicates a higher-than-normal inventory level.To view this press release in Chinese, please visit http://mediaroom.hktdc.com/tcReferences- HKTDC Research website: http://research.hktdc.com/- HKTDC Export Confidence Index 3Q24: Sustained Optimism Underpinned by Strong Sales and New Orders https://research.hktdc.com/en/article/MTgwNDk1NTM5OQPhoto download: https://bit.ly/4deCzLZHKTDC Director of Research Irina Fan (left) and Senior Economist Nicholas Fu (right) announced the HKTDC Export Confidence Index for the third quarter of 2024 at a press conference todayHKTDC Director of Research Irina FanHKTDC Senior Economist Nicholas FuMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.